AMRX
Amneal Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 101 | -4 | 106.56M | $1.84B | +7 | −10 |
| Q1 2026 | 107 | -1 | 100.53M | $1.25B | +9 | −11 |
| Q4 2025 | 109 | 0 | 106.30M | $1.34B | +1 | — |
| Q3 2025 | 18 | 0 | 61.16M | $612.26M | — | — |
| Q2 2025 | 15 | -1 | 52.63M | $425.79M | — | −1 |
| Q1 2025 | 13 | +3 | 21.14M | $177.14M | +3 | — |
| Q4 2024 | 10 | -1 | 20.64M | $163.48M | — | −1 |
| Q3 2024 | 10 | 0 | 16.87M | $140.36M | +2 | −2 |
| Q2 2024 | 10 | — | 16.56M | $105.19M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 9.99M | — | $63.43M | 0.1% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 3.41M | — | $21.65M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 3.41M | — | $21.65M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Millennium Management ✦ | 930.57K | — | $5.91M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Arrowstreet Capital ✦ | 799.34K | — | $5.08M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Renaissance Technologies ✦ | 682.70K | — | $4.34M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 435.08K | — | $2.76M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 435.08K | — | $2.76M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 435.08K | — | $2.76M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 89.89K | — | $570,833 | 0.0% | n/c | 1 | SEC ↗ |
| 11 | Norges Bank ✦ (passive) | 86.20K | — | $547,370 | 0.0% | n/c | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 86.03K | — | $547,000 | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 57.79K | — | $366,954 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 314 holders, 158.91M shares, $1.92B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 50.00K sh · $882,000
Officer · 146.40K sh · $2.56M
Officer · 210.00K sh · $3.65M
Officer · 6.61K sh · $117,050
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
17.6% of class · View original SEC filing ↗
8.4% of class · View original SEC filing ↗
9.4% of class · View original SEC filing ↗